The goal of the company is to improve breast cancer diagnostic tools. According to Čekan, their technology deals with precise and personalised diagnostics, which allow scientists to discover as much as possible about the cancer in a patient’s body in order to know what kind of treatment is necessary. The technology essentially assigns what Čekan calls a "bar code" to each cancer subtype based on RNA biomarkers. His team’s research allows them to increase the accuracy of the diagnosis from 70 to 98 percent.
At the end of 2019, MultiplexDX became the first Slovak company to receive a €2.5 million grant from the European Innovation Council program called EIC Accelerator.
It was a huge success due to being the most-coveted grant among small and medium-sized companies in Europe. More than 2,000 apply for the grant, but only 70 receive it in the end. Čekan explains that his company had to apply ten times to finally get the money and convince the Council that they are capable of delivering.
"This confirms that our research meets high requirements placed on research and development projects worldwide,"
says Čekan. The money will be used to fund pre-clinical trials as well as test and validate the technology on the archived tissues of patients.
During the Covid-19 pandemic, MultiplexDX developed tests to detect the coronavirus. The company donated a great number of the tests to humanitarian causes
and Čekan himself gifted them to the Pope.